share_log

Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $45

Benzinga Real-time News ·  Feb 6, 2023 09:52

Goldman Sachs analyst Matthew Sykes maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $70 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment